Switzerland· 54275129
Exelon
A rivastigmine product containing rivastigminum, registered in Switzerland and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 18 of our 19 countries.
Checked against BAG Spezialitätenliste (Switzerland) on
Informational only — not a medical device.
Where it is registered
Rivastigmine is registered in 18 of 19 countries.
Countries holding a registration under ATC N06DA03 (rivastigmine), each read from that country’s own register.
- This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
- 11 of them publish a price we can compare per daily dose
Rivastigmine · ATC N06DA03
18 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of rivastigmine costs, country by country.
Normalised to the WHO defined daily dose (9 mg), the median price runs from $0.042 in Czechia to $2.19 in Italy — a ×52 gap.
- Switzerland: $1.33 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Rivastigmine · price per daily dose (9 mg)
USD · FX 28 Sept 2026
- IT Italy$2.19
- CH Switzerland$1.33
- CZ Czechia$0.042
The record
At a glance
BAG Spezialitätenliste (Switzerland)- Active substance
- rivastigminum
- Manufacturer
- —
- Country
- Switzerland (CH)
- ATC code
- N06DA03
- ATC class
- Rivastigmine
- Defined daily dose
- 9 mg, O
- Swissmedic category
- B
- Reimbursed
- Yes
- Source register
- BAG Spezialitätenliste (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin768054275129056 StkCHF 60.1
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
235 interactions on record for rivastigmine.
Graded by severity as the source publishes them — 8 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Rivastigmine · interactions on record
235 records
- 8 severe
- 166 moderate
- 59 info
Most severe, free to view
- OzanimodL04AA38severe
- SiponimodL04AA42severe
- OzanimodL04AE02severe
- SiponimodL04AE03severe
2 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Rivastigmine in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomExelon 3mg capsulesWaymade Healthcare Plc
- CzechiaEXELONNovartis Europharm Limited, Dublin
- SpainEXELON 3 mg CAPSULAS DURASNovartis Europharm Limited
- FinlandAcolinAvansor Pharma Oy
- PolandExelonNovartis Europharm Limited
- NetherlandsExelon 3,0 mg, harde capsulesNovartis Europharm Limited
- BelgiumExelon 3 mgNovartis Europharm
- United StatesRivastigmine TartrateAurobindo Pharma Limited
Authorised across Europe · EMA
The same active substance is authorised in 22 EEA countries. Names it is sold under:
- Austria · Nimgista, Rivagelan
- Belgium · Rivastigmin Sandoz, Rivastigmine Viatris
- Bulgaria · Ридаксин
- Germany · Demelora, Rivastigmin
- Denmark · Rigmin, Rivastigmin Orion
- Spain · Alzerta, Alzerta Dos Por Semana
- Finland · Rivastigmin Orion, Rivastigmine Sandoz
- France · Rivastigmine Arrow, Rivastigmine Biogaran
- United Kingdom (Northern Ireland) · Almuriva, Alzest
- Greece · Alapril, Balaxon
- Iceland · Exelon, Nimvastid
- Italy · Demelora, Rivastigmina Aurobindo
- Liechtenstein · Exelon, Rivastigmine 1 A Pharma
- Malta · Rivastigmine Aurobindo
- Netherlands · Ristidic, Rivastgimine Neuraxpharm
- Norway · Exelon, Nimvastid
- Poland · Atmina, Evertas
- Portugal · Nervopan, Rivastigmina Alter
- Romania · Evertas, Ridaxin
- Sweden · Rigmin, Rivastigmin Orion
- Slovenia · Rivastigmin Teva, Rivastigmin Teva B.V.
- Slovakia · Ristidic
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/fa015d0d-b201-4507-a29a-05c73f176de5 GET /v1/drugs/fa015d0d-b201-4507-a29a-05c73f176de5?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "rivastigminum 3 mg",
"valid_from": "1997-03-15",
"limitations": "[{\"description\":\"<b>Symptomatische Behandlung von Patienten mit leichter bis mittelschwerer Demenz vom Typ der Alzheimer Krankheit oder assoziiert mit der Parkinson Krankheit:</b><br>\\nZu Therapiebeginn und regelmässig im Verlauf der Therapie (alle 6 Monate) ist jeweils im Rahmen der klinischen Gesamtbeurteilung (Alltagsfunktion, Verhaltensauffälligkeiten, Kognition) eine Beurteilung der Kognition mittels kognitivem Screening vorzunehmen: Durchführung eines Minimentaltests (mini mental status examination (MMSE), ggf. Umrechnung Montreal Cognitive Assessment (MoCA). Im Stadium schwerer Demenz oder wenn die MMSE-Werte unter 10 liegen, ist die Behandlung zu beenden. Die Behandlung darf nur mit einem Präparat zur Behandlung der Demenz vom Typ der Alzheimer-Krankheit oder assoziiert mit der Parkinson Krankheit durchgeführt werden, eine Kombinationsbehandlung wird nicht vergütet.<br>\",\"costApproval\":null,\"indication\":\"\",\"isNew\":false,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2026-07-01\",\"validTo\":null}]",
"galenic_form": "Kaps 3 mg",
"therapeutic_area": null,
"sl_inclusion_date": "1997-03-15",
"self_retention_pct": 10
}See everything about rivastigmine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.